ALAndrzej Lisowski

Andrzej Lisowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrzej Lisowski has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First report of the isolation and molecular characterisation of Lactococcus garvieae in dairy cattle in Poland

    by Henryk Krukowski, Andrzej Lisowski, Elżbieta Puacz, Witold Chabuz, Małgorzata Targońska-Karasek

    Introduction: Lactococcus garvieae is a catalase-negative, Gram-positive coccus that occurs in pairs and short chains. It is present throughout the world and a causative agent of bovine mastitis. However, prior to writing, no case of mastitis caused by this bacterium had been reported in Poland. The aim of this research was to investigate the presence of L. garvieae in milk samples from Polish cows with inflammation of the mammary gland. Material and Methods: A total of 118 milk samples from 96 Holstein-Friesian cows were spread on blood agar plates for microbial analyses. Then analysis with matrix-assisted laser desorption/ionisation–time-of-flight mass spectrometry, biochemical identification and antibiotic susceptibility evaluation in the VITEK 2 system and a PCR with primers compatible with 16S ribosomal RNA of L. garvieae were performed. Results: The presence of three strains of L. garvieae was confirmed in milk samples. Analysis of antibiotic susceptibility showed the susceptibility of all isolates to moxifloxacin, erythromycin, linezolid, teicoplanin, vancomycin, tetracycline, tigecycline, chloramphenicol and trimethoprim-sulfamethoxazole. Lactococcus garvieae had high resistance to benzylpenicillin, clindamycin and rifampicin. One of the isolated strains was additionally resistant to tetracycline and had different minimum inhibitory concentrations. Conclusion: To the best of our knowledge, L. garvieae had not been identified as an aetiological factor of mastitis in cows in Poland before, and the presented research is the first report.


  • Comparative disposition kinetics of oral deracoxib in sheep and goats

    by Charbel Fadel, Beata Łebkowska‐Wieruszewska, Andrzej Lisowski, Firas Serih, Amnart Poapolathep, Mario Giorgi

    This study investigates the pharmacokinetics (PK) of deracoxib (DX), a selective COX‐2 inhibitor, in sheep and goats following a single oral dose. DX, approved for dogs, holds potential as an alternative NSAID in small ruminants, particularly in light of heightened concern regarding abomasal ulceration. The study employed an oral administration of DX at a dose of 150 mg/head (sheep and goats), and plasma concentrations were determined after validating a high‐performance liquid chromatography method, coupled to a UV detector. The PK parameters, including maximum plasma concentration (C max), time to reach C max (T max), elimination half‐life (t 1/2), and area under the curve (AUC), were evaluated through non‐compartmental analysis. Results showed detectable DX in plasma up to 48 h, with no observed adverse effects. No significant differences in any PK parameters were noted between sheep and goats. Notably, t 1/2 values were relatively long, at 16.66 h for sheep and 22.86 h for goats. Despite the fact that both species exhibited comparable drug exposure, high individual variability was noted within each species, suggesting to take into account individual variations in response to DX treatment, rather than species‐specific considerations. Additional research involving pharmacodynamics and multiple‐dose studies is warranted to comprehensively assess the profile of DX in these species.


  • Open Access

    Disposition kinetics of robenacoxib following intravenous and oral administration in geese (Anser anser domesticus)

    by Charbel Fadel, Beata Łebkowska‐Wieruszewska, Andrzej Lisowski, Seavchou Laut, Amnart Poapolathep, Mario Giorgi

    Robenacoxib (RX) is a veterinary cyclooxygenase‐2 selective inhibitor drug. It has never been tested on birds and is only labelled for use in cats and dogs. The purpose of this study was to assess its pharmacokinetics in geese after single intravenous (IV) and oral (PO) administrations. Four‐month healthy female geese (n = 8) were used. Geese were subjected to a two‐phase, single‐dose (2 mg/kg IV, 4 mg/kg PO), open, longitudinal study design with a four‐month washout period between the IV and the PO phases. Blood was collected from the left wing vein to heparinized tubes at 0, 0.085 (for IV only), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 24 h. Plasma RX concentrations were measured using HPLC coupled to an UV detector, and the data were pharmacokinetically analysed using ThothPro™ 4.3 software in a non‐compartmental approach. Following IV administration, terminal elimination half‐life, volume of distribution, and total clearance were 0.35 h, 0.34 L/kg, and 0.68 L/h/kg, respectively. For the PO route, the mean peak plasma concentration was 6.78 μg/mL at 0.50 h. The t1/2λz was very short and significantly different between the IV and PO administrations (0.35 h IV vs. 0.99 h PO), suggesting the occurrence of a flip‐flop phenomenon. The Cl values corrected for the F% were significantly different between IV and PO administrations. It might have been a consequence of the longitudinal study design and the altered physiological and environmental conditions after a 4‐month washout period. The absolute oral F% computed with the AUC method surpassed 150%, but after normalizing it to t1/2λz, it was 46%. In conclusion, the administration of RX might not be suitable for geese, due to its short t1/2λz.


  • Open Access

    Pharmacokinetics of robenacoxib following single intravenous, subcutaneous and oral administrations in Baladi goats (Capra hircus)

    by Charbel Fadel, Beata Łebkowska‐Wieruszewska, Claudia Zizzadoro, Andrzej Lisowski, Amnart Poapolathep, Mario Giorgi

    The purpose of this study was to assess the pharmacokinetics of robenacoxib (RX), a COX‐2 selective non‐steroidal anti‐inflammatory drug, in goats after single intravenous (IV), subcutaneous (SC) and oral (PO) administrations. 5‐month‐old healthy female goats (n = 8) were used. The animals were subjected to a three‐phase, two‐dose (2 mg/kg IV, 4 mg/kg SC, PO) unblinded, parallel study design, with a four‐month washout period between the IV and SC treatment, and a one‐week period between the SC and PO treatment. Blood was drawn from the jugular vein in heparinized vacutainer tubes at 0, 0.085 (for IV only), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10 and 24 h. Plasma RX concentrations were measured using HPLC coupled to a UV multiple wavelength detector, and the data were pharmacokinetically analysed using ThothPro™ 4.3 software in a non‐compartmental approach. Following IV administration, terminal elimination half‐life, volume of distribution and total clearance were 0.32 h, 0.24 L/kg and 0.52 L/h/kg, respectively. For SC and PO, the mean peak plasma concentrations were 2.34 and 3.34 μg/mL at 1.50 and 0.50 h, respectively. The t1/2λz was significantly different between the IV and the extravascular (EV) administrations (0.32 h IV vs 1.37 h SC and 1.63 h PO), suggesting the occurrence of a flip‐flop phenomenon. The significant difference in Vd values between IV (0.24 L/kg) and EV (0.95 L/kg SC and 1.71 L/kg; corrected for F %) routes might have also triggered the t1/2λz difference. The absolute average SC and PO bioavailability were high (98% and 91%, respectively). In conclusion, the IV administration of RX might not be suitable for goats, due to its short t1/2λz. The EV routes, however, appear to be convenient for the drug's occasional use.


  • Pharmacokinetics of ivermectin after oral and intravenous administration in Biłgorajska geese (Anser anser domesticus)

    by I Sartini, B Łebkowska-Wieruszewska, M Krupa, A Lisowski, A Poapolathep, M Giorgi

    To assess the pharmacokinetic profile of ivermectin in Biłgorajska geese (Anser anser domesticus) after single I/V or oral administration, in order to compare these routes of administration and ass...


  • Open Access

    Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration

    by Charbel Fadel, Beata Łebkowska‐Wieruszewska, Irene Sartini, Andrzej Lisowski, Amnart Poapolathep, Mario Giorgi

    The aim of this study was to evaluate the pharmacokinetics (PK) of robenacoxib (RX), a COX‐2 selective non‐steroidal anti‐inflammatory drug, in sheep after single subcutaneous (SC), oral (PO), and intravenous (IV) administration. Five healthy female sheep underwent a three‐phase parallel study design with a washout period of 4 weeks, in which sheep received a 4 mg/kg SC dose in phase 1, a 4 mg/kg PO administration in phase 2, and a 2 mg/kg IV administration in phase 3. Plasma RX concentrations were measured over a 48 h period for each treatment using HPLC coupled to a UV multiple wavelength detector, and the PK parameters were estimated using a non‐compartmental method. Following IV administration, terminal elimination half‐life, volume of distribution at steady state, and total clearance were 2.64 h, 0.077 L/kg, and 0.056 L/h kg, respectively. The mean peak plasma concentrations following SC and PO administrations were 7.04 and 3.01 μg/mL, respectively. The mean bioavailability following SC and PO administrations were 45.98% and 16.58%, respectively. The SC route may be proposed for use in sheep. However, the multi‐dose and pharmacodynamic studies are necessary to establish more accurately its safety and efficacy in sheep.


  • Single and multiple oral amoxicillin treatment in geese: a pharmacokinetic evaluation

    by Irene Sartini, Beata Łebkowska-Wieruszewska, Charbel Fadel, Andrzej Lisowski, Amnart Poapolathep, Mario Giorgi

    Although amoxicillin has broad-spectrum antibiotic activity and is extensive used in poultry, its use has never been investigated in geese. This study aimed to evaluate the pharmacokinetics of amoxicillin after a single and multiple oral doses in geese. A total of 20 geese were enrolled in this study and randomly pooled in two groups (n=10). In group I, animals were treated with a single oral 20 mg/kg dose of amoxicillin, while group II were administered multiple doses (20 mg/kg/day for 4 days). Concentrations of amoxicillin in plasma were analyzed using a validated HPLC-UV method and drug plasma concentrations were modeled for each subject using a non-compartmental approach. Amoxicillin showed rapid absorption after a single dose treatment, with an elimination half-life of approximately 1 h. Cmax, Tmax and AUC values differed statistically between groups I and II (after the first dose administered). A large variability was observed in the pharmacokinetic profiles and drug accumulation may occur after the multiple administration. No accumulation in plasma was predicted from an in-silico simulation performed using the same multiple dosage schedule. The in-silico simulation does not seem to accurately predict in-field conditions.


  • Open Access

    Doxycycline pharmacokinetics in geese

    by Irene Sartini, Beata Łebkowska‐Wieruszewska, Andrzej Lisowski, Amnart Poapolathep, Andrejs Sitovs, Mario Giorgi

    The study aims to describe the pharmacokinetics of doxycycline after a single intravenous and oral dose (20 mg/kg) in geese. In addition, two multiple‐dose simulations have been performed to investigate the predicted plasma concentration after either a 10 or 20 mg/kg daily administration repeated consecutively for 5 days. Ten geese were enrolled in a two‐phase cross‐over study with a washout period of two weeks. All animals were treated intravenously and orally with doxycycline, and blood samples were collected up to 48 h after drug administration. Sample analysis was performed using a validated HPLC‐UV method. A non‐compartmental approach was used to evaluate the pharmacokinetic parameters of the drug. A long elimination half‐life was observed (13 h). The area under the curve was statistically different between the two treatments, with the oral bioavailability being moderate (43%). The pharmacokinetic/pharmacodynamic index (%T>MIC) during the 48 h treatment period in the present study (71%) suggests that doxycycline appears to have therapeutic efficacy against some Mycoplasma species in the goose. The multiple‐dose simulations showed a low accumulation index. A dosage of 10 mg/kg/day for 5 days seemed to be adequate for a good therapeutic efficacy without reaching unnecessarily high plasma concentrations.


  • Levofloxacin pharmacokinetics and tissue residue concentrations after oral administration in Bilgorajska geese

    by I. Sartini, B. Łebkowska-Wieruszewska, A. Sitovs, A. Lisowski, A. Poapolathep, M. Giorgi

    1. The aim of this study was to assess the pharmacokinetics of levofloxacin, a third-generation fluoro-quinolone antimicrobial drug, in geese (n = 26) after either single intravenous or oral administration, and to evaluate the depletion profile in goose muscle, heart, liver, kidney and lung after a single oral dose. 2. The pharmacokinetic study involved 16 geese which were randomly divided into two groups (n = 8/group), the first received levofloxacin (2 mg/kg) intravenously while the second was treated with orally (5 mg/kg). The tissue depletion study involved 10 geese which were dosed orally (5 mg/kg) and two animals were killed at different time-points in order to collect the selected tissues. Levofloxacin was quantified in all the matrices tested by a validated high-performance liquid chromatography (HPLC) method, using a spectrofluorimetric detector. The pharmacokinetics were analysed using a non-compartmental model. 3. Plasma concentrations were quantified after up to 24 h in animals administered intravenously and up to 48 h after oral treatment. Levofloxacin was rapidly absorbed after oral administration (T-max = 0.38 h) showing high bioavailability (95.57 +/- 20.61%). The drug showed a moderate volume of distribution (1.40 +/- 0.28 ml/g) and rapid clearance (0.28 +/- 0.06 ml/g/h). No statistical differences in estimates were found between the two different administration methods (P > 0.05). Drug residues were highest at 6 h and decreased constantly up to 48 h in all the selected tissues. Liver and kidney had the highest levofloxacin concentrations. 4. According to the pharmacokinetic/pharmacodynamic surrogate index (AUC/MIC) the levofloxacin dose regimen (after oral administration) used in the present study could be active against bacteria at a minimum inhibitory concentration (MIC) > 0.24 mu g/ml in geese. In addition, drug accumulation in the liver might be controlled using an estimated preliminary withdrawal time of 90 h.


  • Pharmacokinetics of acetaminophen after intravenous and oral administration in fasted and fed Labrador Retriever dogs

    by Irene Sartini, Beata Łebkowska‐Wieruszewska, Andrzej Lisowski, Amnart Poapolathep, Barbara Cuniberti, Mario Giorgi

    Acetaminophen (paracetamol) is used in dogs to manage fever and mild pain. The aim of this study was to assess the pharmacokinetics of acetaminophen in both fed and fasted Labrador Retrievers after a single intravenous and oral administration (20 mg/kg). Six healthy dogs underwent three treatments in a randomized block study (a,n = 2; b,n = 2; c,n = 2). In phase one, group a received acetaminophen intravenously, group b and c orally after being fasted and fed, respectively. In phase two and three, groups were swapped, and the experiment was repeated. At the end of the trial, each dog received the same treatment. Acetaminophen plasma concentrations were detected using a validated HPLC‐UV method. The pharmacokinetic analysis was performed using a noncompartmental model. Clearance, volume at steady state and half‐life of acetaminophen in Labrador Retrievers were 0.42 L/kg hr, 0.87 L/kg and 1.35 hr, respectively. No significant statistical differences were found between fasted and fed dogs regarding maximum plasma concentration, time at maximum concentration and bioavailability as measured by the AUC. Feeding does not significantly affect the acetaminophen oral pharmacokinetics.